Triple-negative breast cancer (estrogen receptor-, progesterone receptor-, and HER2-negative) (TNBC) is a high risk breast cancer that lacks specific therapy targeting these proteins. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.